The Trial Without Walls: How Real-World Evidence Is Rewriting the Rul…

Real-world evidence (RWE) from routine clinical practice can now substitute for traditional randomised control arms in drug trials through trial emulation methodology, but FDA and ICH guidance remains incomplete on disease-specific thresholds and data quality standards. Sponsors are redesigning Phase 3 programs mid-cycle to exploit this regulatory shift, though underlying real-world data quality—not methodology—remains the critical barrier to approval. If you're running a Phase 3 oncology trial, the FDA is now willing to accept real-world patient data instead of a randomised control arm—but only if your data source is cleaner and more complete than most EHR systems are today. You have eighteen months to decide whether to redesign your trial around this before your competitors force the pace.